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Histone deacetylases (HDAC) extensively contribute to the c-Myc oncogenic program, pointing to their inhibition as an effec-
tive strategy against c-Myc-overexpressing cancers. We, thus, studied the therapeutic activity of the new-generation pan-HDAC
inhibitor ITF2357 (GivinostatVR ) against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas (B-NHLs). ITF2357 anti-
proliferative and pro-apoptotic effects were analyzed in B-NHL cell lines with c-Myc translocations (Namalwa, Raji and DOHH-2),
stabilizing mutations (Raji) or post-transcriptional alterations (SU-DHL-4) in relationship to c-Myc modulation. ITF2357 signifi-
cantly delayed the in vitro growth of all B-NHL cell lines by inducing G1 cell-cycle arrest, eventually followed by cell death. These
events correlated with the extent of c-Myc protein, but not mRNA, downregulation, indicating the involvement of post-
transcriptional mechanisms. Accordingly, c-Myc-targeting microRNAs let-7a and miR-26a were induced in all treated lymphomas
and the cap-dependent translation machinery components 4E-BP1, eIF4E and eIF4G, as well as their upstream regulators, Akt
and PIM kinases, were inhibited in function of the cell sensitivity to ITF2357, and, in turn, c-Myc downregulation. In vivo,
ITF2357 significantly hampered the growth of Namalwa and Raji xenografts in immunodeficient mice. Noteworthy, its combina-
tion with suboptimal cyclophosphamide, achieved complete remissions in most animals and equaled or even exceeded the activ-
ity of optimal cyclophosphamide. Collectively, our findings provide the rationale for testing the clinical advantages of adding
ITF2357 to current therapies for the still very ominous c-Myc-overexpressing lymphomas. They equally provide the proof-of-
concept for its clinical evaluation in rational combination with the promising inhibitors of B-cell receptor and PI3K/Akt/mTOR
axis currently in the process of development.
Deregulated expression of c-Myc transcription factor plays a
critical role in the pathogenesis and progression of aggressive
B-cell NHLs (B-NHLs) and multiple myeloma.1,2 The prime
example of c-Myc-driven oncogenesis is Burkitt’s lymphoma
(BL), a highly aggressive and fast-growing B-NHL, in which
chromosomal translocations juxtaposing c-Myc with the pro-
moter regions of immunoglobulin (Ig)-coding genes are vir-
tually invariant, early oncogenic events.3 Although the
prognosis of BL has been signiﬁcantly ameliorated by inten-
sive chemotherapy regimens,4 treatment-related toxicity is
still a signiﬁcant problem.4,5 In addition, accumulating evi-
dence is showing that c-Myc overexpression also deﬁnes a
subgroup of aggressive B-NHLs across different histotypes,
including transformed follicular, marginal zone, mantle cell
and diffuse large B-cell lymphomas (DLBCL), with an
extremely poor prognosis due to enhanced chemoresistance
and aggressiveness.1,6–8 This points to the urgent need for
novel and more effective treatments for these diseases.
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The clear causative role of c-Myc overexpression in B-cell
lymphomagenesis9,10 and its frequent association with an
unfavorable prognosis6,7 indicate that interfering with c-
Myc’s oncogenic functions may secure a better outcome. c-
Myc is unique in its ability to bind approximately 10–15% of
all human genes,11 where it controls transcription via recruit-
ment of speciﬁc co-activators or co-repressors, such as,
respectively, histone acetyl-transferase (HATs)12 or DNA
methyltransferase and histone deacetylases (HDACs).13–16
The transforming potential of c-Myc overexpression stems
from its functions to promote cell proliferation, alter cell
metabolism and favor genomic instability. For this reason, its
expression is normally kept under tight control by several
safeguard mechanisms, whose evasion/inactivation is a pre-
requisite for c-Myc-driven lymphomagenesis.17,18
Although several lines of evidence have established c-Myc
as a reliable lymphoma therapeutic target,10,19 strategies for
its direct inhibition have not yet been successful probably
because of the lack of a clear ligand-binding domain. The
current understanding that c-Myc oncogenic gene expression
reprogramming mostly relies on epigenetic changes makes
HDAC inhibitors novel suitable drug candidates for the treat-
ment of c-Myc-overexpressing lymphomas. This view has
been further strengthened by recent demonstrations of their
ability to downregulate c-Myc expression itself in different
oncotypes, including Hodgkin lymphoma.20,21 However,
whether and how HDAC inhibitors can achieve this effect
also in human c-Myc overexpressing (c-Myc1) B-cell NHLs
as well as the resulting therapeutic impact against these dis-
eases have not yet been speciﬁcally investigated.
Therefore, we looked to see whether HDAC pan-inhibition
by the new-generation hydroxamate derivative ITF2357
(GivinostatVR ) was able to counteract c-Myc oncogenic func-
tions in preclinical human c-Myc1 B-NHL models, and could
thus constitute a useful addition to the treatment armamentar-
ium for these diseases. In line with our hypothesis, we found
that ITF2357 antiproliferative activity was proportional to
c-Myc down-modulation in c-Myc1 B-NHL models. Inter-
estingly, c-Myc reduction was limited to its protein levels
and occurred independently from the presence of a C-MYC-
IG translocation, indicating the involvement of post-
transcriptional mechanisms. In view of the crucial bidirectional
interplay between c-Myc and microRNAs (miRNAs), in
particular let-7a and miR-26a,22–24 and the requirement of
cap-dependent translation initiation machinery25 to ensure
constitutive high levels of c-Myc protein expression, we specif-
ically tested whether ITF2357 could affect these molecules. We
found that let-7a and miR-26a were induced and cap-
dependent translation initiation machinery inhibited after
treatment, thus contributing to explain the persistent down-
modulation of c-Myc protein. In two mouse models of human
BL, ITF2357 provided the same molecular effects and signiﬁ-
cantly enhanced the therapeutic activity of cyclophosphamide
(CTX), leading to long-lasting complete responses. Taken as a
whole, these ﬁndings strongly highlight the therapeutic advan-
tages of ITF2357 to concurrently abrogate multiple oncogenic
pathways regulating c-Myc expression in c-Myc1 B-NHLs.
They equally provide the proof-of-concept for its clinical eval-
uation in rational combination with available anticancer agents
to improve the treatment of these diseases.
Material and Methods
Cells lines
Human B-NHL cell lines Namalwa (BL), Raji (BL), SU-DHL-
4 (DLBCL) and DOHH-2 (C-MYC-IG translocated follicular
lymphoma [FL]) (DSMZ, Braunschweig, Germany) were cul-
tured in RPMI 1640 medium (Lonza, Switzerland) supple-
mented with 10% (volume/volume) inactivated FBS (Lonza)
and 1% (volume/volume) L-glutamine (Lonza) in a humidi-
ﬁed chamber with 5% CO2 at 37C. Viable cells in treated
and untreated cultures were measured with the trypan blue
exclusion test.
Drugs
ITF2357 (diethyl-[6-(4-hydroxycarbamoyl-phenyl carbamoy-
loxymethyl)-naphthalen-2-yl methyl]-ammonium chloride;
monohydrate; Italfarmaco, patent WO 97/43251, US
6034096) was kindly provided by Italfarmaco (Milan, Italy).
CTX was from Baxter (Endoxan, Baxter).
Flow cytometry analyses
Flow cytometry of apoptosis and the cell cycle were per-
formed as previously described.26,27
For c-Myc intracellular staining, cells were treated with
ﬁxation and permeabilization buffers (eBioscience San Diego,
CA) and incubated with a rabbit anti-human c-Myc mono-
clonal antibody (mAb) (Cell Signaling Technology), and a
FITC-labeled goat anti-rabbit IgG (KPL) as a secondary Ab.
Healthy donor peripheral blood mononuclear cell (PBMC)
samples were stained with APC-labeled anti-human CD19
What’s new?
c-Myc plays a critical role in aggressive B-cell non-Hodgkin lymphomas and multiple myelomas, and is associated with
extremely poor prognosis. It hasn’t been easy, though, to directly inhibit c-Myc. In this study, the authors found that a
histone-deacetylase inhibitor (HDAC) called ITF2357 down-regulated c-Myc protein expression, and that microRNAs (miRNAs)
may be involved. ITF2357 also significantly enhanced chemotherapy against human Burkitt’s lymphoma in mice. These results
suggest that indirectly interfering with c-Myc’s oncogenic functions is a promising therapeutic strategy, and that ITF2357 may
be a valuable addition to conventional treatments for c-Myc-overexpressing lymphomas.
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Figure 1. Cytotoxic and cytostatic effects of ITF2357 in c-Myc1 B-NHL cultures. Raji, Namalwa, SU-DHL-4 and DOHH-2 cells were incubated
for the indicated period (hr) with 0.2 mM ITF2357 supplied as a single (ITF) or a daily treatment (dITF), or were not treated (NT) as control,
and cell proliferation (left), cell-cycle progression (middle) and apoptosis induction (right) were assessed in culture at 24-hr intervals. Cell
proliferation is represented as fold increase (FI) in viable cells with respect to the seeded cell number (left). Frequencies of cells in G1
(dark gray), S (white) and G2 (light gray) cell-cycle phases measured by flow cytometry are shown as histograms (middle). Apoptosis levels
in treated or untreated cultures were determined by flow cytometry analysis of annexin V (ANN V) and PI co-staining (white, viable ANN V-
PI-cells %; light gray, early apoptotic ANN V1PI2 cells %; dark gray, late apoptotic ANN V1PI1 cells % and black, necrotic ANN V2PI1
cells %) (right). Data are the mean6SE of at least four independent experiments. Statistically significant differences between treated and
untreated cells (black asterisks) or between ITF and dITF treatments (gray asterisks) within the same time point were assessed with the
unpaired two-tailed Student’s t test (*P<0.05; ** P<0.01; *** P<0.001).
mAb (BD Biosciences) before being processed for c-Myc
intracellular staining.
Data were acquired on a BD FACSCalibur using BD Cell-
Quest software version 3.3 (Becton Dickinson) and analyzed
by FlowJo 8.8.7 software version for Macintosh (Tree Star).
Western blot analyses
Lymphoma cells were solubilized in Laemli buffer as previ-
ously described,26 or in RIPA buffer (Cell Signaling Technol-
ogy), according to the manufacturer’s instructions.
Histones extraction was performed by lysing cells in PBS
containing 0.5% v/v Triton X 100, 2 mM phenylmethylsulfo-
nyl ﬂuoride, 0.02% w/v NaN, for 10 min on ice. After centrif-
ugation at 6,5003g for 10 min, nuclear pellets were washed
in lysis buffer and incubated overnight at 4C in 0.2 N HCl.
Histones were recovered in the supernatant after centrifuga-
tion at 6,5003g for 10 min.
Western blotting was performed as already reported26 by using
primary Abs directed against the following human proteins: a-
tubulin (1:2,000) (Invitrogen), p21 (1:1,000), p27 (1:1,000) and
phosphorylated(p)-4E-binding protein-1 (p-4E-BP1) (1:300)
(Santa Cruz Biotechnology, Santa Cruz, CA); p-p53 (Ser15)
(1:1,000) and p53 (1:1,000) (Dako, Denmark); poly-ADP-ribose
polymerase (PARP) (1: 1,000) (BD Biosciences); 4E-BP1, p-
eukaryotic initiation factor 4E (p-eIF4E) (Ser 209), eIF4E, p-eIF4G
(Ser1108), eIF4G, p-Akt (Thr 308), Akt, PIM1, PIM2, PIM3, ace-
tylated(Ac)-H3 histone (Lys 9), Ac-H4 histone, H3 histone and c-
Myc (1:1,000) (Cell Signaling Technology); Ac-p53 and Ac-a-
tubulin (Lys 40) (1:3,000), vinculin and b-actin (1:1,000) (Sigma-
Aldrich, Seattle, WA); H4 histone (1:1,000) (Abcam, Cambridge,
Figure 2. Expression analysis of molecular pathways associated with ITF2357 anti-lymphoma activity. (a) Representative western blot analy-
ses of the indicated proteins in Raji, Namalwa, SU-DHL-4 and DOHH-2 cells cultured in the absence (NT) or presence of 0.2 mM ITF2357
administered once or every 24 hr (daily, d) for the indicated hours. Cellular vinculin content is shown as an internal protein loading control.
Images were acquired by using Microtek ArtixScan F1, and cropped to retain the relevant bands with Adobe Photoshop CS version 4 for
Macintosh computer. (b) Relative c-Myc mRNA expression levels measured by qRT-PCR in the same culture conditions described in (a). In
each condition, c-Myc mRNA levels, upon normalization relative to GAPDH transcript, are expressed as fold change with respect to
untreated cultures at any time point. Data are the mean6SE of five independent experiments.
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Figure 3. Expression of c-Myc-regulating miRNAs and cap-dependent translation initiation machinery in ITF2357-treated B-NHL cell lines. (a)
Expression of let-7a (top) and miR-26a (bottom) in Raji, Namalwa, SU-DHL-4 and DOHH-2 cells incubated for the indicated hours with 0.2
mM ITF2357, or untreated as control (NT). Data are shown as fold change in miRNA expression levels relative to the one found in untreated
cultures for each time point and represent the mean6SE of three independent experiments. Significant differences between treated and
untreated samples at any time point were calculated with the unpaired two-tailed Student’s t test (*P<0.05, ** P<0.01). (b) Representa-
tive western blot analyses of cap-dependent translation initiation complex and its molecular regulators in Raji, Namalwa, SU-DHL-4 and
DOHH-2 cells cultured in the absence (NT) or presence of 0.2 mM ITF2357 administered once or every 24 hr (daily, d) for the indicated
hours. Cellular vinculin content is shown as an internal protein loading control. Images were acquired by using Microtek ArtixScan F1, and
cropped to retain the relevant bands with Adobe Photoshop CS version 4 for Macintosh computer.
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UK). Membranes were then incubated with the appropriate HRP-
conjugated secondary Abs (Amersham) in blocking solution, and
signals were visualized with an enhanced ECL system (GE Health-
care) according to themanufacturer’s protocol.
RNA extraction, reverse transcription and real-time
quantitative PCR analysis
Total RNA was extracted by using Trizol reagent (Invitro-
gen). Total RNA was reverse-transcribed using Super-Script
III reagents (Invitrogen). Levels of c-Myc transcript were nor-
malized relative to glyceraldehyde-3-phosphate dehydro-
genase (GAPDH), b-actin or hypoxanthine-guanine
phosphoribosyltransferase (HPRT) mRNA by using the
appropriate TaqMan probes (Applied Biosystems).
To detect and quantify mature miRNAs, the TaqMan
MicroRNA Reverse Transcription Kit (Applied Biosystems)
was used according to the manufacturer’s protocol.
Real time quantitative PCR (qRT-PCR) was carried out in
an ABI PRISM 7900 machine (Applied Biosystems). Data
were analyzed by applying the 2ð2DCtÞ calculation method.
Figure 4. In vivo anti-lymphoma activity of ITF2357 in combination with CTX. (a) Growth of subcutaneous Raji (left) and Namalwa (right)
tumors in SCID mice treated for 3 weeks with CTX following an optimal (75 mg/kg/week, light gray) or a suboptimal (50 mg/kg/week, dark
gray) schedule, or with ITF2357 alone (50 mg/kg/day, dotted black) or in combination with suboptimal CTX (CTX 501 ITF2357, dotted gray)
or with saline as control (black). Data show the average tumor volumes6SE of 8 (Raji) or 7 (Namalwa) mice treated in each group from
one out of two independent experiments. Statistically significant differences in treated compared with untreated animals (black asterisks)
and between CTX 502 or CTX 752 and CTX 501 ITF2357-treated groups (dark and light gray asterisks, respectively) were calculated by
using the two-way ANOVA (*P<0.05; ** P<0.01; *** P<0.001). (b) Ratio between Ki-67-immunostained area and the total nuclear area,
measured by ImageJ software analysis version146 in five high-power microscopic fields of tumor sections from ITF2357-treated (1) and
control (2) biopsies. The boxes extend from the 25th to the 75th percentiles, the lines indicate the median values, and the whiskers indi-
cate the range of values. Significant differences between treated and untreated samples were calculated with the unpaired two-tailed Stu-
dent’s t test (**P<0.01; ***P<0.001; ns, not significant). (c) Progression-free survival curves of Raji-xenografted mice treated for 3 weeks
with optimal (CTX 75, light gray), or suboptimal (CTX 50, dark gray) CTX or the combination CTX 501 ITF2357 (dotted gray), which were
monitored for up to 112 days for disease recurrence. Statistically significant differences between CTX 502 or CTX 752 and CTX 501
ITF2357-treated groups (dark and light gray asterisks, respectively) were calculated by using the log rank test (*P<0.05; ** P<0.01).
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miRNA inhibition
For miRNA inhibition, 3 3 105 cells (Raji, SU-DHL-4 and
DOHH-2) were transiently transfected with LNA-let-7a, or
LNA-miR-26a, or a negative control (Exiqon) at a ﬁnal con-
centration of 100 nM by using the SiPort Neo-FX reagent
(Ambion, Austin, TX) according to the manufacturer’s
instructions. After 18 hr, cells were treated or not with 0.2
mM ITF2357 for additional 24 or 48 hr, and then processed
for miRNA detection by qRT-PCR and c-Myc evaluation by
western blot.
In vivo experiments
Severe combined immunodeﬁciency mice (SCID) (Charles
River) were subcutaneously injected with 10 3 106 tumor
cells, and, when tumor volumes reached about 50 mm,3
treated with 0.9% NaCl, 50 mg/kg ITF2357 (5 daily oral
administrations/week), 75 (optimal) or 50 (suboptimal) mg/
kg CTX (1 injection/week) or 50mg/kg CTX plus ITF2357
for 3 weeks. Mice were then sacriﬁced, tumor xenografts
excised and processed for western blot, qRT-PCR and immu-
nohistochemistry (IHC) analyses. Brieﬂy, formalin-ﬁxed and
parafﬁn-embedded tissue sections, after antigen retrieval in
citrate buffer (Novocastra, UK), were incubated overnight
with mouse anti-human Ki67 mAb (Dako, Denmark). Immu-
nostaining was revealed with the polymer detection kit
(Novocastra) and 3,31-Diaminobenzidine as chromogenic
substrate. Tissue sections were lastly counterstained with
Harris hematoxylin (Novocastra).
Experimental protocols were approved by the Ethical
Committee for Animal Experimentation of the Fondazione
IRCCS Istituto Nazionale per lo Studio e la Cura dei Tumori
(Milan, Italy), according to the Italian legislation (Legislative
Order No. 116 of 1992, as amended), which implements the
EU 86/109 Directive.
Statistical analyses
Two-sided Student’s t test and two-way ANOVA with Bon-
ferroni post-test were used to detect statistically signiﬁcant
differences. Signiﬁcant differences in disease recurrence
between treatment groups were assessed by the log rank test.
Pearson correlation coefﬁcient was calculated to measure
dependence between variables. Statistical analyses were per-
formed on the Prism 5.0a software (GraphPad Software) ver-
sion for Macintosh Pro personal computer.
Results
Cytostatic and cytotoxic in vitro activity of ITF2357 against
c-Myc1 B-NHL cell lines
We tested the antitumor activity of ITF2357 on human BL
(Namalwa and Raji), DLBCL (SU-DHL-4) and FL (DOHH-
2) cell lines that overexpress c-Myc (Supporting Information
Fig. S1) as a consequence of genetic abnormalities, including
translocation under Ig promoter regions (Namalwa, Raji and
DOHH-2), and mutations conferring c-Myc protein stabiliza-
tion (Raji),17 or post-transcriptional alterations (SU-DHL-
4).28 In vitro treatment with increasing concentrations of
ITF2357 (0–0.8 mM) resulted in a time- and dose-dependent
cell-growth delay, and after 48-hr incubation the average
IC50 was approximately 0.2 mM, as measured by a standard
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium assay (data
not shown). The subsequent in vitro experiments were thus
performed using ITF2357 at 0.2 mM, as a single or daily
treatment, in view of the transient HDAC inhibition provided
by this compound.29
A single administration of 0.2 mM ITF2357 almost com-
pletely blocked proliferation in all cell lines for at least 72 hr,
with DOHH-2, Namalwa, SU-DHL-4 and Raji displaying
respectively 866 2%, 836 2%, 796 1%, 696 3% growth
inhibition after 72 hr (Fig. 1 left). This effect was associated
with a rapid cell-cycle arrest in the G1 phase (Fig. 1 middle,
dark gray), which in Raji and SU-DHL-4 cultures signiﬁ-
cantly persisted for up to 144 hr in the absence of daily
retreatment. DOHH-2 and Namalwa cells, which experienced
a less persistent cell-cycle arrest, were instead the most sensi-
tive to the cytotoxic effects of ITF2357 (Fig. 1 right). Interest-
ingly, daily retreatment also extensively killed SU-DHL-4
Table 1. Antitumor effects of ITF2357 and/or CTX in SCID mice xenotransplanted with human BL cell lines
Namalwa Raji
Drug1 Dose (mg/kg) Schedule Max TVI%2 (day) Tox/Tot3 (day) CR4 (day) Max TWI%2 (day) Tox/Tot3 (day) CR4 (day)
ITF2357 50 qdx5/wx6w 42.7 (24) 0/7 0/7 (24) 50.6 (35) 0/8 0/8 (55)
CTX 75 q7dx3 99.6 (24) 0/7 1/7 (17) 98.6 (39) 2/8 (31, 39) 1/8 (112)
CTX 50 q7dx3 97.8 (17) 0/7 0/7 (24) 95.4 (39) 0/8 0/8 (74)
ITF2357 50 qdx5/wx6w
99.9 (24) 0/7 4/7 (24) 99.2 (39) 0/8 5/8 (35)
1 CTX 50 q7dx3
1CTX was dissolved in saline; ITF2357 in DMSO:cremophor:PBS (10:5:85).
2MaxTVI, percentage of maximum tumor volume inhibition; in brackets, the day after tumor inoculums.
3Tox/Tot, any death in treated mice occurring before any in control mice; in brackets, the day after tumor inoculums.
4CR, complete tumor regression lasting at least 1 week.
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cells, but was not able to signiﬁcantly boost apoptosis in Raji
cultures (Fig. 1 right).
ITF2357-mediated modulation of cytostatic and pro-
apoptotic molecular signals
The cytostatic and cytotoxic effects of ITF2357 were con-
ﬁrmed by p21 and p27 upregulation and PARP cleavage
induction in treated compared with untreated cultures (Fig.
2a). The kinetic of the latter event, in particular, reﬂected the
different ITF2357 sensitivity of the cell lines tested, with
Namalwa and DOHH-2 cells more persistently showing
cleaved PARP after a single drug administration, SU-DHL-4
and Raji—the latter to a more limited extent—only in case of
daily retreatment (Fig. 2a). None of these effects seemed to
be related to the activation of p53, as they were not associ-
ated with either its stabilization or increased phosphorylation
at Ser15 (Fig. 2a). Accordingly, despite an augmented acetyla-
tion level of both nuclear and cytoplasmic proteins in treated
cells (Supporting Information Fig. S2), the fraction of acety-
lated p53 tended to decrease (Fig. 2a). The cytostatic and
cytotoxic effects of ITF2357 appeared instead to be more
closely associated with c-Myc reduction (Fig. 2a and Support-
ing Information Fig. S3a). Indeed, the extent of c-Myc pro-
tein downregulation in ITF2357-treated lymphoma cell lines
positively correlated with PARP cleavage at all time points,
and was thus associated with their sensitivity to ITF2357
pro-apoptotic activity (Pearson r5 0.6449, P5 0.0021, Sup-
porting Information Fig. S4a). In addition, 72 hr after a sin-
gle administration of ITF2357, which approximately marked
the end of its antitumor activity (Fig. 1, left), the degree of c-
Myc protein down-modulation (Supporting Information Fig.
S3a; Raji: 546 7%; SU-DHL-4: 696 6%; Namalwa: 796 4%;
DOHH-2: 926 8%) positively correlated with the extent of
growth inhibition in lymphoma cultures (Person r5 0.9807,
P5 0.0193, Supporting Information Fig. 4b). This indicates
that, in c-Myc1 B-NHLs, ITF2357 exerts its antitumor
effects in function of its ability of impairing c-Myc expres-
sion, and points to c-Myc downregulation as a potential use-
ful biomarker for its activity. ITF2357-mediated reduction of
c-Myc expression does not appear to depend on the presence
Figure 5. In vivo ITF2357-mediated anti-lymphoma effects. Expression of (a) c-Myc protein (left) and mRNA (right), (b) let-7a (left) and miR-
26a (right) and (c) activation status of cap-dependent translation initiation machinery and its upstream regulatory molecules in pooled
ITF2357-treated (1) or control (2) tumor biopsies, harvested from Raji- and Namalwa-xenografted mice after 3 weeks of treatment. Signifi-
cant differences between treated and untreated samples were calculated with the unpaired two-tailed Student’s t test (*P<0.05;
**P<0.01; ***P<0.00).
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of a C-MYC-IG translocation, but may be hampered when
the stable c-Myc(T58A) mutant is expressed, as occurs in
Raji cells,17 in which extensively daily retreatment was
required to induce this effect. Interestingly, c-Myc mRNA did
not signiﬁcantly decrease after treatment (Fig. 2b, Supporting
Information Fig. S3b), pointing to ITF2357’s ability of prefer-
entially altering the post-transcriptional regulation of c-Myc
expression.
ITF2357 interference with the post-transcriptional control
of c-Myc expression
To ﬁnd out the molecular pathways involved in ITF2357-
mediated post-transcriptional c-Myc downregulation, we ini-
tially determined whether ITF2357 speciﬁcally alters the
expression of let-7a and miR-26a, the most relevant miRNAs
in the control of c-Myc expression.14,22,23 Indeed, c-Myc con-
stitutes a direct target of translation inhibition mediated by
let-7a,23 and the ﬁnal target in one of its crucial positive for-
ward loop blocked by miR-26a.14 Interestingly, in all cellular
models, both miRNAs were signiﬁcantly up-regulated for at
least 48 hr after a single treatment (Fig. 3a). To further docu-
ment the signiﬁcance of this effect, we found that interfering
with these miRNAs partially rescued c-Myc downregulation
induced by ITF2357 (Supporting Information Fig. S5).
As an additional mechanism that could account for c-Myc
post-transcriptional repression, we then investigated whether
ITF2357 also altered the activation status of the cap-
dependent translation initiation machinery, which is known
to speciﬁcally control c-Myc protein expression.25 This pro-
cess is activated by the transfer of m7G-cap-binding protein
eIF4E from its repressor 4E-BP1 to eIF4G, the central scaf-
fold protein of the eIF4F translation initiation complex,
where their further phosphorylation stabilizes the interactions
required for correct positioning of ribosomal subunits on the
m7G-cap of mRNA and translation initiation.30 Akt and PIM
kinases are the best-deﬁned signaling hubs regulating cap-
dependent translation.31 Upon mTOR activation, Akt phos-
phorylates and inactivates 4E-BP1.30 On the other hand, PIM
kinases increase eIF4E expression and phosphorylation.31
Noteworthy, in all cell lines, ITF2357 reduced the phospho-
rylation status of 4E-BP1, eIF4E and eIF4G as well (Fig. 3b
and Supporting Information Fig. S6). Once again, the degree
of these effects was associated with the extent of c-Myc
downregulation and PARP cleavage in ITF2357-treated cells.
In particular, Namalwa and DOHH-2 also most persistently
deactivated these proteins after a single ITF2357 administra-
tion, whereas Raji and SU-DHL-4 cells most often required
daily retreatment (Fig. 3b and Supporting Information
Fig. S6). Intriguingly, the expression levels of eIF4G total pro-
tein also decreased in all cell lines, whereas those of 4E-BP1
and eIF4E speciﬁcally decreased in Namalwa and DOHH-2
cells (Fig. 3b). To clarify how ITF2357 was able to affect cap-
dependent translation, we looked to see whether it altered the
expression and activation of its major regulators. In all cell
lines, a single treatment potently decreased the expression
levels of all three PIM kinase isoforms, whereas it was not
always associated with Akt dephosphorylation (Fig. 3b).
However, the last effect could not explain the different sensi-
tivity to ITF2357, as phospho-Akt was also being expressed
in daily retreated SU-DHL-4 (Fig. 3b), which displayed high
level of PARP cleavage and apoptosis (Figs. 1, 2a). Accord-
ingly, even in the case of no reduction in phospho-Akt, inhi-
bition of eIF4E and eIF4G was still achieved (Fig. 3b),
probably due to the continuous inhibition of PIM kinases
that control cap-dependent translation at a more downstream
level compared with the PI3K/Akt/mTOR pathway.31,32
These results illustrate the ability of ITF2357 to interfere
in different c-Myc1 B-cell NHL histotypes with the two
major post-transcriptional regulators of protein expression—
namely miRNAs and cap-dependent translation—that are
speciﬁcally required for the tight control of c-Myc.
In vivo anti-lymphoma effects of ITF2357 in combination
with standard chemotherapy
We then veriﬁed whether the effects demonstrated in vitro by
ITF2357 enhanced the in vivo anti-lymphoma activity of con-
ventional chemotherapy. SCID mice with sizable subcutane-
ous Raji or Namalwa tumors were treated daily for 3 weeks
with ITF2357 alone or in combination with three courses of
a suboptimal dose (50 mg/kg) of CTX. As controls, other
groups received in parallel saline or CTX at optimal (75 mg/
kg) or suboptimal (50 mg/kg) dose alone. The dosage and
schedule of ITF2357 administration was chosen in the light
of preliminary experiments showing that, under these condi-
tions, it was well tolerated with no signs of toxicity (data not
shown). Accordingly, no signiﬁcant body-weight loss and no
death occurred in ITF2357-treated mice earlier than in the
controls (Table 1). In comparison with untreated mice,
ITF2357 signiﬁcantly delayed the in vivo growth of both Raji
and Namalwa cells and led to a 50.6% and 42.7% reduction
in tumor burden respectively after 3 weeks (Table 1, Fig. 4a,
dotted black line versus black line). This was associated with
a signiﬁcant downregulation of Ki-67 expression, highlighting
the capability of the drug to hamper the growing potential of
both these highly aggressive lymphomas (Fig. 4b, Supporting
Information Fig. S7).
Full-dose CTX completely inhibited lymphoma growth
(Fig. 4a light gray lines), but was not able to eradicate the
disease in the most animals (Table 1). Treatment with subop-
timal CTX dose was only able to control tumor growth to a
similar extent in Raji-xenografted mice; indeed, after the sec-
ond course, Namalwa nodules started to increase exponen-
tially (Fig. 4a right, dark gray line). Addition of ITF2357
signiﬁcantly enhanced the therapeutic effects of low-dose
CTX in both models (Fig. 4a, dotted gray line versus dark
gray lines), where the combination brought about a complete
response (CR) in 60% of mice (Table 1). Furthermore, in
Raji-xenografted mice, where low-dose CTX was sufﬁcient to
block tumor growth, this combination also compared favor-
ably with optimal CTX alone (Fig. 4a left, dotted gray versus
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light gray line). The slower in vivo engraftment of Raji com-
pared to Namalwa cells (Fig. 4a, black lines), despite a com-
parably marked and widespread Ki-67 positivity (Fig. 4b,
Supporting Information Fig. S7) which indicates their suscep-
tibility to the cytotoxic effect of an alkylating agent, may pro-
vide one explanation for the different outcome of low-dose
CTX, and, in turn, its combination with ITF2357 in these
models.
The limited tumor burden in Raji-xenografted mice after
3 weeks of treatment with either optimal or suboptimal CTX
or its combination with ITF2357 allowed monitoring of
tumor growth for an additional 13 weeks. Mice that had
received the combination were treated with ITF2357 alone
for a further 3 weeks. This resulted in complete disease eradi-
cation in 37.5% of the animals, which remained disease free
at 112 days after tumor injection (Fig. 4c, dotted dark gray
line), in sharp contrast with CTX, which, even at the highest
dose, reached a long-lasting disease stabilization only in one
case (Fig. 4c, light gray line).
In line with the in vitro ﬁndings, in vivo treatment with
ITF2357 resulted in c-Myc downregulation at protein (Fig. 5a
left), but not mRNA level (Fig. 5a right), induction of let-7a
(Fig. 5b left; Raji, P5 0.0013; Namalwa, P< 0.0001) and
miR-26a (Fig. 5b right; Raji, P5 0.03; Namalwa, P5 0.001),
and reduction of 4E-BP1 and eIF4E phosphorylation in both
the models analyzed (Fig. 5c). Daily exposure to ITF2357 for
21 days in vivo might have favored the occurrence of these
molecular effects also in Raji cells, which in this condition
displayed similarly marked molecular modulations with
respect to Namalwa xenografts (Fig. 5). In addition, not only
the expression of PIM kinases, but also Akt phosphorylation
was signiﬁcantly downregulated in both Namalwa and Raji
treated biopsies (Fig. 5c), highlighting the ability of ITF2357
treatment to interfere in vivo with both mechanisms that
positively control cap-dependent translation initiation.
Discussion
Our study demonstrates that the pan-HDAC inhibitor
ITF2357 potently down-regulates c-Myc protein expression
in a panel of human c-Myc-overexpressing B-NHL cell lines
independently from the presence of a C-MYC translocation.
This effect led inevitably to cell-cycle arrest, and correlated
with apoptosis induction and cell-growth inhibition. The con-
current induction of let-7a and miR-26a and inhibition of
cap-dependent translation initiation machinery provides
some explanations of the persistent c-Myc repression after
ITF2357 treatment. In vivo administration of ITF2357 signiﬁ-
cantly delayed the growth of human BL xenografts, and its
combination with a suboptimal CTX treatment clearly
enhanced the anti-lymphoma activity of either agent used
alone, and brought about durable complete remissions.
The effectiveness of suppressing c-Myc as an anti-
lymphoma option has been widely established;10,19,33 how-
ever, its direct pharmacologic inhibition has remained elusive
due to the absence of a deﬁned ligand-binding domain.
Alternative strategies are now focusing on the selective target-
ing of c-Myc oncogenic functions.33,34 In this context, the
emerging cooperation between c-Myc and HDACs13–15 indi-
cates that inhibiting these enzymes may turn out to be prom-
ising against c-Myc-driven tumors. Recent studies have also
revealed the ability of HDAC inhibitors, such as vorinostat,
sodium butyrate and depsipeptide to down-regulate not only
c-Myc transcriptional activity, but also c-Myc expression
itself in both hematologic and solid malignancies, thus con-
stituting a double-edged sword against c-Myc-overexpressing
malignancies.20,21 Building upon the ﬁnding that HDAC7
binding to the C-MYC genetic sequence is required for its
efﬁcient transcription,35 the possibility that HDACs directly
regulate the chromatin architecture of C-MYC has been pro-
posed as a mechanism accounting for its downregulation fol-
lowing their inhibition.
However, in all c-Myc1 B-NHL cell lines tested in this
study, we show that ITF2357 reduces c-Myc protein but not
mRNA levels, through at least two mechanisms: upregulation
of the c-Myc-regulating miRNAs let-7a and miR-26a and
inhibition of the molecular pathway required for its transla-
tion. Several ﬁndings point to a greater sensitivity of c-Myc
expression to miRNAs-mediated impairment of protein syn-
thesis rather than transcript stability, as demonstrated by (i)
the lack of a perfect complementarity between c-Myc mRNA
and its major regulatory miRNA, let-7a, a condition that usu-
ally favors the induction of mRNA degradation;23 (ii) the
presence of c-Myc mRNA-miRNA complexes almost exclu-
sively within functional polysomes and not in translationally
inactive subpolysomal particles, where mRNA cleavage usu-
ally happens;24,36 (iii) and further recent evidence that
miRNAs-mediated c-Myc repression occurs at a translation
post-initiation phase.37 In keeping with our results, previous
reports have shown that let-7a and miR-26a are widely
repressed in tumors overexpressing c-Myc,22,23 and that their
upregulation in aggressive human B-NHL cell lines, including
those used in this study, is associated with c-Myc inhibition
and cell-growth arrest.14,16,23,24,38 Whereas let-7a directly tar-
gets c-Myc, miR-26a is a key node of a more complex loop
regulating c-Myc expression, as it represses the methyltrans-
ferase EZH2 thereby releasing its inhibition on miR-494, a
recently described c-Myc-targeting miRNA.14 To ensures its
constitutive expression and maintain its lymphomagenic pro-
gram, c-Myc counteracts this circuit by directly repressing
miR-26a, thus disinhibiting EZH2 and blocking miR-494
expression. Increasing evidence is pointing to a crucial pro-
oncogenic role of EZH2 in germinal-center-derived B-
NHLs,39 where its concurrent inhibition with c-Myc results
in a synergic antitumor effect associated with miR-26a resto-
ration.16 Even if we cannot rule out that in our models miR-
26a induction is the consequence of c-Myc downregulation
by other mechanisms here described, this effect may
strengthen the level of c-Myc inhibition and at the same time
counteract a well-established pro-lymphomagenic circuit. On
the other hand, the observation that miRNA genes are also
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controlled by epigenetic modulations14–16,40 raises the
hypothesis that miRNA induction after ITF2357 treatment is
a consequence of the direct promotion of histone acetylation
at their loci.
Nonetheless, interfering with let-7a and miR-26a did not
completely rescue the ability of ITF2357 to inhibit c-Myc
expression, pointing to the potential concurrent blockade of c-
Myc protein synthesis. In line with our hypothesis, we found
that ITF2357 signiﬁcantly impaired the processes leading to c-
Myc protein synthesis and stabilization, thus reinforcing its
anti-Myc activity. In cancer, activation of cap-dependent trans-
lation via eIF4E de-repression and binding to eIF4G within the
eIF4F translation initiation complex, coupled with the concur-
rent phosphorylation of these molecules, ensures the production
of short-lived oncoproteins, including c-Myc.25 PI3K/Akt/
mTOR axis and, further downstream, PIM kinases are the key
regulators of cap-dependent translation activation.41 Besides
their common ability of activating c-Myc translation, these mol-
ecules favor c-Myc protein stability42,43 and genetic transactiva-
tion,12 thus contributing at several levels to c-Myc
overexpression. In keeping with this ﬁnding, a wide body of evi-
dence is highlighting their crucial involvement in c-Myc-driven
lymphomagenesis, as the activation of either PI3K,44 PIM
kinases,32,41 or eIF4E45 signiﬁcantly accelerate tumor formation
in Em-MYC models, indicating a pro-lymphoma cooperation
between c-Myc overexpression and these pathways. Interest-
ingly, PIM kinases are speciﬁcally overexpressed in FL,41
DLBCL46 and mantle cell lymphoma47 with a poor response to
conventional treatments and have thus been proposed as poten-
tial valuable therapeutic targets in these diseases. In this context,
the ability of ITF2357 to down-modulate all PIM kinases, deac-
tivate key components of the cap-dependent translation initia-
tion machinery while promoting 4E-BP1 inhibitory functions in
different aggressive B-NHL models highlights its substantial
therapeutic potential. Given the addiction of cancer cells to cap-
dependent translation, inhibition of this process at the most
downstream level by ITF2357 might constitute a useful thera-
peutic option to counteract the aberrant PI3K/Akt/mTOR sig-
naling cascade commonly activated in B-NHLs44,48 and sensitize
tumor cells to apoptosis. Accordingly, in all lymphoma cell lines
tested in our study, ITF2357 reduced the activity of cap-
dependent translation even when Akt was not inhibited.
At present, we can only speculate about the potential
mechanisms through which ITF2357 inhibits PIM kinases.
Nonetheless, all the reported levels of control for their expres-
sion may be in principle affected by ITF2357. Indeed, protein
synthesis of PIM kinases requires the activity of cap-
dependent translation, and their stability the presence of
molecular chaperones and the downregulation of speciﬁc miR-
NAs.32 We have demonstrated that ITF2357 inhibits cap-
dependent translation and alters the miRNA expression pat-
tern, whereas the function of HDAC inhibition to impair heat
shock protein 90 chaperone activity has been extensively
reported,49 thus providing an initial explanation for ITF2357’s
ability to repress PIM kinases. This ﬁnding for the ﬁrst time
indicates that the reported difﬁculties of developing a unique
PIM kinase inhibitor32 might be easily overcome by using a
pan-HDAC inhibitor that is already clinically available.50
All together these ITF2357-mediated molecular effects sig-
niﬁcantly enhanced the in vivo anti-lymphoma activity of a
suboptimal and well-tolerated dose of CTX, bringing its efﬁ-
cacy at least to the level of the optimal treatment, while
reducing its toxicity. The possibility to further extend the
therapeutic potential of this combination seems to rely on
the capability of the chemotherapeutic agent to control the in
vivo lymphoma growth.
In conclusion, at least in the context of c-Myc1 human
B-NHLs, ITF2357 treatment provides signiﬁcant anti-
lymphoma effects in association with its many-sided ability
to counteract c-Myc overexpression, which can thus be con-
sidered as a reliable biomarker for its activity. This, however,
does not exclude the effectiveness of ITF2357 against other
oncotypes, considering that the pleiotropic effects of HDAC
inhibitors strictly rely on the biologic context they encounter.
Even though the mechanisms through which ITF2357 consis-
tently induces let-7a and miR-26a, and inhibits PIM kinases
and cap-dependent translation in Myc1 B-NHLs are not
fully elucidated, the opportunity to provide all these effects
with a single agent may be of a substantial therapeutic
advantage, given that they have already demonstrated a sig-
niﬁcant anti-lymphoma activity individually.16,23,38,41,45 For
these reasons, ITF2357 may constitute a valuable addition to
conventional anti-lymphoma chemotherapy for the treatment
of the still very ominous c-Myc-overexpressing B-NHLs.6–8
In addition, our ﬁndings highlight the importance of testing
the therapeutic advantages of ITF2357 in combination with
the wide array of novel agents able to interfere with the
PI3K/Akt/mTOR pathway and/or EZH2 activity, which sig-
niﬁcantly boost c-Myc-driven lymphomagenesis.44,48
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